

Supplementary Table S1: CD9 and CD81 Gene expression analysis

DATASET	COMPARISON	n NORMAL	n CANCER	n TOTAL	P Value
TCGA	Prostate Adenocarcinoma vs. Normal	61	45	106	0.861
Wallace	Prostate Adenocarcinoma vs. Normal	20	69	89	0.993
Vanaja	Prostate Adenocarcinoma vs. Normal	8	27	35	0.64
Lapointe	Prostate Carcinoma vs. Normal	41	62	103	1
Yu	Prostate Carcinoma vs. Normal	23	65	88	0.356
Taylor	Prostate Carcinoma vs. Normal	29	31	60	0.786
Liu	Prostate Carcinoma vs. Normal	13	44	57	0.946
Holzbeierlein	Prostate Carcinoma vs. Normal	4	40	44	0.342
Luo	Prostate Carcinoma vs. Normal	15	15	30	0.523
LaTulippe	Prostate Carcinoma vs. Normal	3	23	26	0.245
Arredouani	Prostate Carcinoma vs. Normal	8	13	21	0.897
Varambally	Prostate Carcinoma vs. Normal	6	7	13	0.084
Magee	Prostate Carcinoma vs. Normal	4	8	12	0.98
Tomlins	Prostatic Intraepithelial Neoplasia Epithelia vs. Norm	16	13	29	0.934
TCGA	Prostate Adenocarcinoma vs. Normal	61	45	106	0.35

Vanaja	Prostate Adenocarcinoma vs. Normal	8	27	35	0.93
Tomlins	Prostate Carcinoma Epithelia vs. Normal	13	10	23	0.777
Taylor	Prostate Carcinoma vs. Normal	29	131	160	1
Singh	Prostate Carcinoma vs. Normal	50	52	102	0.289
Lapointe	Prostate Carcinoma vs. Normal	39	60	99	0.897
Yu	Prostate Carcinoma vs. Normal	23	65	88	0.987
Grasso	Prostate Carcinoma vs. Normal	28	59	87	1
Liu	Prostate Carcinoma vs. Normal	13	44	57	0.998
Holzbeierlein	Prostate Carcinoma vs. Normal	4	40	44	0.912
Welsh	Prostate Carcinoma vs. Normal	9	25	34	0.814
Luo	Prostate Carcinoma vs. Normal	15	15	30	0.955
LaTulippe	Prostate Carcinoma vs. Normal	3	23	26	0.992
Arredouani	Prostate Carcinoma vs. Normal	8	13	21	0.999
Varambally	Prostate Carcinoma vs. Normal	6	7	13	0.997

Magee	Prostate Carcinoma vs. Normal	4	8	12	0.991
-------	-------------------------------	---	---	----	-------

REFERENCE

The Cancer Genome Atlas - Prostate Adenocarcinoma DNA Copy Number Data

Tumor immunobiological differences in prostate cancer between African-American and European-American men. *Cancer Res.* 2008 Feb 1;68(3):927-36.

Vanaja DK, Chevillat JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. *Cancer Res.* 2003 Jul 15;63(14):3877-82.

P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. *Proc Natl Acad Sci U S A.* 2004 Jan 20;101(3):811-6. Epub 2004 Jan 7.

Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *J Clin Oncol.* 2004 Jul 15;22(14):2790-9.

Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. *Cancer Cell.* 2010

Moreno CS. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. *Cancer Res.* 2006 Apr 15;66(8):4011-9.

WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am J Pathol.* 2004 Jan;164(1):217-27.

prostate cancers. *Mol Carcinog.* 2002 Jan;33(1):25-35.

prostate cancer reveals distinct transcriptional programs associated with metastatic disease. *Cancer Res.* 2002 Aug 1;62(15):4499-506.

Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. *Clin Cancer Res.* 2009 Sep 15;15(18):5794-802.

Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell.* 2005 Nov;8(5):393-406.

Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. *Cancer Res.* 2001 Aug 1;61(15):5692-6.

Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. *Nat Genet.* 2007 Jan;39(1):41-51.

The Cancer Genome Atlas - Prostate Adenocarcinoma DNA Copy Number Data

<p>Vanaja DK, Chevillie JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. <i>Cancer Res.</i> 2003 Jul 15;63(14):3877-82.</p>
<p>Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. <i>Nat Genet.</i> 2007 Jan;39(1):41-51.</p>
<p>Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. <i>Cancer Cell.</i> 2010</p>
<p>Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. <i>Cancer Cell.</i> 2002 Mar;1(2):203-9.</p>
<p>P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. <i>Proc Natl Acad Sci U S A.</i> 2004 Jan 20;101(3):811-6. Epub 2004 Jan 7.</p>
<p>Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. <i>J Clin Oncol.</i> 2004 Jul 15;22(14):2790-9.</p>
<p>IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature.</i> 2012 Jul 12;487(7406):239-43.</p>
<p>Moreno CS. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. <i>Cancer Res.</i> 2006 Apr 15;66(8):4011-9.</p>
<p>WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. <i>Am J Pathol.</i> 2004 Jan;164(1):217-27.</p>
<p>expression identifies candidate markers and pharmacological targets in prostate cancer. <i>Cancer Res.</i> 2001 Aug 15;61(16):5974-8.</p>
<p>prostate cancers. <i>Mol Carcinog.</i> 2002 Jan;33(1):25-35.</p>
<p>prostate cancer reveals distinct transcriptional programs associated with metastatic disease. <i>Cancer Res.</i> 2002 Aug 1;62(15):4499-506.</p>
<p>Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. <i>Clin Cancer Res.</i> 2009 Sep 15;15(18):5794-802.</p>
<p>Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell.</i> 2005 Nov;8(5):393-406.</p>

Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. *Cancer Res.* 2001 Aug 1;61(15):5692-6.